<p>2025 年 11 月 13 日- 上午 08:39</p>
<p>馬里蘭州貝塞斯達 --（商業資訊）-- <strong>Global Medical REIT Inc. (NYSE:GMRE)</strong>（“公司”）今天宣佈開始進行其系列 B 累積可贖回優先股的承銷公開發行，面值每股 0.001 美元（“系列 B 優先股”），具體情況取決於市場和其他條件。公司預計將授予承銷商 30 天的選擇權，以購買額外的系列 B 優先股以覆蓋超額配售（如有）。公司打算將此次發行的淨收益用於一般企業用途，包括資助新收購和償還債務，包括公司信貸額度下的未償還金額。</p>
<p>公司打算申請在紐約證券交易所上市系列 B 優先股，股票代碼為 “GMRE-PrB”。</p>
<p>Raymond James、BMO 資本市場、Stifel 和 Baird 擔任此次發行的賬簿管理人。</p>
<p>此次發行是根據公司已修訂的貨架註冊聲明進行的，該聲明於 2024 年 4 月 4 日獲得美國證券交易委員會（“SEC”）的有效聲明。與此次發行相關的初步招股説明書補充及附帶招股説明書將提交給 SEC，並可從 SEC 網站 www.sec.gov 獲取，或通過以下方式聯繫：Raymond James &amp; Associates, Inc.，注意：股權承銷部，880 Carillon Parkway, St. Petersburg, Florida 33716，電話：(800) 248-8863，或通過電子郵件聯繫：prospectus@raymondjames.com；BMO Capital Markets Corp.，注意：股權承銷部，151 W 42nd Street, 32nd Floor, New York, NY 10036，或通過電子郵件聯繫：bmoprospectus@bmo.com；Stifel, Nicolaus &amp; Company, Incorporated，注意：承銷部，1201 Wills Street, Suite 600, Baltimore, MD 21231，或通過電子郵件聯繫：syndprospectus@stifel.com；Robert W. Baird &amp; Co. Incorporated，注意：承銷部，777 E. Wisconsin Avenue, Milwaukee, WI 53202，電話：800-792-2473，電子郵件：syndicate@rwbaird.com。</p>
<p>本新聞稿不構成出售要約或購買要約的招攬，也不應在任何州進行這些股份或其他證券的銷售，若該等要約、招攬或銷售在任何州違反證券法，則在註冊或資格之前。</p>
<p><strong>關於 Global Medical REIT Inc.</strong></p>
<p>Global Medical REIT Inc.是一家淨租賃醫療房地產投資信託，收購醫療設施並將這些設施租賃給醫生集團及區域和國家醫療系統。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿中包含的某些聲明可能被視為 1995 年《私人證券訴訟改革法》意義上的 “前瞻性聲明”，公司意圖使任何此類聲明受到該法案所創建的安全港保護。這些前瞻性聲明通過使用 “預期”、“相信”、“可能”、“估計”、“期望”、“打算”、“可能”、“應該”、“計劃”、“預測”、“項目”、“將”、“繼續” 等術語和短語以及對未來結果的假設和預測的引用來識別。本新聞稿中的前瞻性聲明示例包括關於系列 B 優先股擬議發行、預計的發行收益用途以及系列 B 優先股在紐約證券交易所上市的聲明。這些前瞻性聲明基於我們當前的預期、估計和假設，並受到某些風險和不確定性的影響。儘管公司相信其前瞻性聲明中反映的預期、估計和假設是合理的，但實際結果可能與公司前瞻性聲明中預測或假設的結果有重大差異。有關公司及其業務的更多信息，包括可能對其財務結果產生重大不利影響的其他因素，包括但不限於在公司 10-K 表格年報的第一部分第 1A 項 - 風險因素中描述的風險。您被警告不要對前瞻性聲明過度依賴。公司不打算，也不承擔更新任何前瞻性聲明的義務。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTExMTMyNzMyMTdyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTExMTMyNzMyMTdyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251113273217/en/</p>
<p><strong>投資者關係：</strong></p>
<p>電子郵件：Investors@globalmedicalreit.com</p>
<p>電話：202.524.6869</p>
<p>來源：Global Medical REIT Inc.</p>

GMRE

<p>全球醫療房地產投資信託公司（Global Medical REIT Inc.）宣佈將進行一項系列 B 優先股的公開發行，具體情況將視市場條件而定。此次發行包括承銷商在 30 天內購買額外股份的選擇權。所得款項將用於公司用途，包括收購和債務償還。該股票將在紐約證券交易所上市，代碼為 “GMRE-PrB”。Raymond James、BMO Capital Markets、Stifel 和 Baird 正在管理此次發行。此次發行是在公司已獲美國證券交易委員會（SEC）批准的貨架註冊聲明下進行的</p>

<p>11/13/2025 - 08:39 AM</p>
<div class="lb-trans"><p>2025 年 11 月 13 日- 上午 08:39</p>
</div><p>BETHESDA, Md.--(BUSINESS WIRE)-- <strong>Global Medical REIT Inc. (NYSE:GMRE)</strong>(the “Company”) today announced the commencement of an underwritten public offering of shares of its Series B Cumulative Redeemable Preferred Stock, $0.001 par value per share (“Series B Preferred Stock”), subject to market and other conditions. The Company expects to grant the underwriters a 30-day option to purchase additional shares of Series B Preferred Stock to cover over-allotments, if any. The Company intends to use the net proceeds from the offering for general corporate purposes, which may include funding new acquisitions and repaying indebtedness, including amounts outstanding under the Company’s credit facility.</p>
<div class="lb-trans"><p>馬里蘭州貝塞斯達 --（商業資訊）-- <strong>Global Medical REIT Inc. (NYSE:GMRE)</strong>（“公司”）今天宣佈開始進行其系列 B 累積可贖回優先股的承銷公開發行，面值每股 0.001 美元（“系列 B 優先股”），具體情況取決於市場和其他條件。公司預計將授予承銷商 30 天的選擇權，以購買額外的系列 B 優先股以覆蓋超額配售（如有）。公司打算將此次發行的淨收益用於一般企業用途，包括資助新收購和償還債務，包括公司信貸額度下的未償還金額。</p>
</div><p>The Company intends to apply to list the Series B Preferred Stock on the New York Stock Exchange under the ticker symbol “GMRE-PrB.”</p>
<div class="lb-trans"><p>公司打算申請在紐約證券交易所上市系列 B 優先股，股票代碼為 “GMRE-PrB”。</p>
</div><p>Raymond James, BMO Capital Markets, Stifel and Baird are serving as the book-running managers for the offering.</p>
<div class="lb-trans"><p>Raymond James、BMO 資本市場、Stifel 和 Baird 擔任此次發行的賬簿管理人。</p>
</div><p>The offering is being made pursuant to the Company’s shelf registration statement, as amended, which was declared effective by the U.S. Securities and Exchange Commission (“SEC”) on April 4, 2024. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering, which will be filed with the SEC and may be obtained from the SEC’s website at www.sec.gov or by contacting: Raymond James &amp; Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, by telephone at (800) 248-8863, or by email at prospectus@raymondjames.com; BMO Capital Markets Corp., Attn: Equity Syndicate Department, 151 W 42nd Street, 32nd Floor, New York, NY 10036, or by email at bmoprospectus@bmo.com; Stifel, Nicolaus &amp; Company, Incorporated, Attention: Syndicate Department, 1201 Wills Street, Suite 600, Baltimore, MD 21231, or by email at syndprospectus@stifel.com; and Robert W. Baird &amp; Co. Incorporated, Attention: Syndicate Department, 777 E. Wisconsin Avenue, Milwaukee, WI 53202, telephone: 800-792-2473, email: syndicate@rwbaird.com.</p>
<div class="lb-trans"><p>此次發行是根據公司已修訂的貨架註冊聲明進行的，該聲明於 2024 年 4 月 4 日獲得美國證券交易委員會（“SEC”）的有效聲明。與此次發行相關的初步招股説明書補充及附帶招股説明書將提交給 SEC，並可從 SEC 網站 www.sec.gov 獲取，或通過以下方式聯繫：Raymond James &amp; Associates, Inc.，注意：股權承銷部，880 Carillon Parkway, St. Petersburg, Florida 33716，電話：(800) 248-8863，或通過電子郵件聯繫：prospectus@raymondjames.com；BMO Capital Markets Corp.，注意：股權承銷部，151 W 42nd Street, 32nd Floor, New York, NY 10036，或通過電子郵件聯繫：bmoprospectus@bmo.com；Stifel, Nicolaus &amp; Company, Incorporated，注意：承銷部，1201 Wills Street, Suite 600, Baltimore, MD 21231，或通過電子郵件聯繫：syndprospectus@stifel.com；Robert W. Baird &amp; Co. Incorporated，注意：承銷部，777 E. Wisconsin Avenue, Milwaukee, WI 53202，電話：800-792-2473，電子郵件：syndicate@rwbaird.com。</p>
</div><p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these shares or any other securities in any state in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any state.</p>
<div class="lb-trans"><p>本新聞稿不構成出售要約或購買要約的招攬，也不應在任何州進行這些股份或其他證券的銷售，若該等要約、招攬或銷售在任何州違反證券法，則在註冊或資格之前。</p>
</div><p><strong>About Global Medical REIT Inc.</strong></p>
<div class="lb-trans"><p><strong>關於 Global Medical REIT Inc.</strong></p>
</div><p>Global Medical REIT Inc. is a net-lease medical REIT that acquires healthcare facilities and leases those facilities to physician groups and regional and national healthcare systems.</p>
<div class="lb-trans"><p>Global Medical REIT Inc.是一家淨租賃醫療房地產投資信託，收購醫療設施並將這些設施租賃給醫生集團及區域和國家醫療系統。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>Certain statements contained in this press release may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and it is the Company’s intent that any such statements be protected by the safe harbor created thereby. These forward-looking statements are identified by their use of terms and phrases such as &#34;anticipate,&#34; &#34;believe,&#34; &#34;could,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;may,&#34; &#34;should,&#34; &#34;plan,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;will,&#34; &#34;continue&#34; and other similar terms and phrases, including references to assumptions and forecasts of future results. Examples of forward-looking statements in this press release include statements regarding the proposed offering of the Series B Preferred Stock, the expected use of proceeds from the offering and the listing of shares of Series B Preferred Stock on the New York Stock Exchange. These forward-looking statements are based on our current expectations, estimates and assumptions and are subject to certain risks and uncertainties. Although the Company believes that the expectations, estimates and assumptions reflected in its forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of the Company’s forward-looking statements. Additional information concerning the Company and its business, including additional factors that could materially and adversely affect its financial results, include, without limitation, the risks described under Part I, Item 1A - Risk Factors, in the Company’s Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and in its other filings with the SEC. You are cautioned not to place undue reliance on forward-looking statements. The Company does not intend, and undertakes no obligation, to update any forward-looking statement.</p>
<div class="lb-trans"><p>本新聞稿中包含的某些聲明可能被視為 1995 年《私人證券訴訟改革法》意義上的 “前瞻性聲明”，公司意圖使任何此類聲明受到該法案所創建的安全港保護。這些前瞻性聲明通過使用 “預期”、“相信”、“可能”、“估計”、“期望”、“打算”、“可能”、“應該”、“計劃”、“預測”、“項目”、“將”、“繼續” 等術語和短語以及對未來結果的假設和預測的引用來識別。本新聞稿中的前瞻性聲明示例包括關於系列 B 優先股擬議發行、預計的發行收益用途以及系列 B 優先股在紐約證券交易所上市的聲明。這些前瞻性聲明基於我們當前的預期、估計和假設，並受到某些風險和不確定性的影響。儘管公司相信其前瞻性聲明中反映的預期、估計和假設是合理的，但實際結果可能與公司前瞻性聲明中預測或假設的結果有重大差異。有關公司及其業務的更多信息，包括可能對其財務結果產生重大不利影響的其他因素，包括但不限於在公司 10-K 表格年報的第一部分第 1A 項 - 風險因素中描述的風險。您被警告不要對前瞻性聲明過度依賴。公司不打算，也不承擔更新任何前瞻性聲明的義務。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTExMTMyNzMyMTdyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251113273217r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251113273217/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251113273217/en/</p>
</div><p><strong>Investor Relations:</strong></p>
<div class="lb-trans"><p><strong>投資者關係：</strong></p>
</div><p>Email: Investors@globalmedicalreit.com</p>
<div class="lb-trans"><p>電子郵件：Investors@globalmedicalreit.com</p>
</div><p>Phone: 202.524.6869</p>
<div class="lb-trans"><p>電話：202.524.6869</p>
</div><p>Source: Global Medical REIT Inc.</p>
<div class="lb-trans"><p>來源：Global Medical REIT Inc.</p>
</div>

Global Medical REIT Inc. 宣佈計劃公開發行 B 系列優先股 | GMRE 股票新聞